[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR9909549A - Formas cristalinas do 1s-[1alfa(2s*,3r*),9alfa]-6, 10-dioxo-n(2-etóxi-5-oxo-tetrahidro-3-furanil)-9-[[(1-is oquinolil)carbonil]-amino]octa-hidro-6h-piridazino[1 ,2-a][1,2]diazepina-1-carboxamida - Google Patents

Formas cristalinas do 1s-[1alfa(2s*,3r*),9alfa]-6, 10-dioxo-n(2-etóxi-5-oxo-tetrahidro-3-furanil)-9-[[(1-is oquinolil)carbonil]-amino]octa-hidro-6h-piridazino[1 ,2-a][1,2]diazepina-1-carboxamida

Info

Publication number
BR9909549A
BR9909549A BR9909549-1A BR9909549A BR9909549A BR 9909549 A BR9909549 A BR 9909549A BR 9909549 A BR9909549 A BR 9909549A BR 9909549 A BR9909549 A BR 9909549A
Authority
BR
Brazil
Prior art keywords
diazepine
dioxo
oxo
amino
crystalline forms
Prior art date
Application number
BR9909549-1A
Other languages
English (en)
Inventor
Jean-Yves Godard
Valerie Rognon
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of BR9909549A publication Critical patent/BR9909549A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"FORMAS CRISTALINAS DO 1S-[1ALFA(2S*,3R*),9ALFA]-6,10-DIOXO-N-(2-ETóXI-5-OXO-TET RAHIDRO-3-FURANIL)-9-[[(1-ISOQUINOLIL)CARBONIL]-AMINO] OCTAHIDRO-6H-PIRIDAZINO[1,2-A][1,2]DIAZEPINA-1-CARBOX AMIDA"<D>. A invenção tem por objeto as novas formas cristalinas do 1S-[1alfa(2S*,3R*), 9alfa]6,10-dioxo-N-(2-etóxi-5-oxo-tetra-hidro-3-furanil)-9[[1-isoquinolil) carbonil]amino]octahidro-6H-piridazino[1,2-a][1,2]diazepina-1-carbo xamida anidro (forma A) e hidratado (forma B), seu processo de preparo, sua aplicação a título de medicamento e as composições farmacêuticas que os contêm.
BR9909549-1A 1998-04-08 1999-04-07 Formas cristalinas do 1s-[1alfa(2s*,3r*),9alfa]-6, 10-dioxo-n(2-etóxi-5-oxo-tetrahidro-3-furanil)-9-[[(1-is oquinolil)carbonil]-amino]octa-hidro-6h-piridazino[1 ,2-a][1,2]diazepina-1-carboxamida BR9909549A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9804367A FR2777279B1 (fr) 1998-04-08 1998-04-08 Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
PCT/FR1999/000799 WO1999052935A1 (fr) 1998-04-08 1999-04-07 Formes cristallines du 1s-[1alpha (2s*,3r*),9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9-[[(1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino[1, 2-a][1,2] diazepine-1- carboxamide

Publications (1)

Publication Number Publication Date
BR9909549A true BR9909549A (pt) 2000-12-12

Family

ID=9524993

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909549-1A BR9909549A (pt) 1998-04-08 1999-04-07 Formas cristalinas do 1s-[1alfa(2s*,3r*),9alfa]-6, 10-dioxo-n(2-etóxi-5-oxo-tetrahidro-3-furanil)-9-[[(1-is oquinolil)carbonil]-amino]octa-hidro-6h-piridazino[1 ,2-a][1,2]diazepina-1-carboxamida

Country Status (38)

Country Link
US (2) US6544977B1 (pt)
EP (1) EP1070083B1 (pt)
JP (1) JP2002511485A (pt)
KR (1) KR100582981B1 (pt)
CN (1) CN1202123C (pt)
AP (1) AP1734A (pt)
AR (1) AR018328A1 (pt)
AT (1) ATE315044T1 (pt)
AU (1) AU758042B2 (pt)
BG (1) BG64736B1 (pt)
BR (1) BR9909549A (pt)
CA (1) CA2325629C (pt)
CU (1) CU23055A3 (pt)
CZ (1) CZ299744B6 (pt)
DE (1) DE69929315T2 (pt)
DK (1) DK1070083T3 (pt)
EA (1) EA002761B1 (pt)
EE (1) EE04467B1 (pt)
ES (1) ES2253880T3 (pt)
FR (1) FR2777279B1 (pt)
GE (1) GEP20032974B (pt)
HK (1) HK1038575B (pt)
HR (1) HRP20000665B1 (pt)
HU (1) HU227561B1 (pt)
ID (1) ID26290A (pt)
IL (2) IL138818A (pt)
ME (1) ME01627B (pt)
NO (1) NO327995B1 (pt)
NZ (1) NZ507199A (pt)
PL (1) PL197016B1 (pt)
RS (1) RS49916B (pt)
SI (1) SI1070083T1 (pt)
SK (1) SK286267B6 (pt)
TR (1) TR200002914T2 (pt)
TW (1) TW522152B (pt)
UA (1) UA71563C2 (pt)
WO (1) WO1999052935A1 (pt)
ZA (1) ZA200005438B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150468A (en) * 2006-06-30 2014-01-30 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
AU2014277867B2 (en) * 2007-12-04 2016-11-03 Arbutus Biopharma Corporation Targeting lipids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors

Also Published As

Publication number Publication date
HRP20000665B1 (en) 2008-01-31
JP2002511485A (ja) 2002-04-16
CA2325629A1 (fr) 1999-10-21
AU3041699A (en) 1999-11-01
HK1038575B (zh) 2006-01-06
ES2253880T3 (es) 2006-06-01
FR2777279A1 (fr) 1999-10-15
EA200001047A1 (ru) 2001-04-23
CZ299744B6 (cs) 2008-11-12
EP1070083B1 (fr) 2006-01-04
EA002761B1 (ru) 2002-08-29
CN1202123C (zh) 2005-05-18
HK1038575A1 (en) 2002-03-22
CA2325629C (fr) 2013-01-22
EE04467B1 (et) 2005-04-15
BG64736B1 (bg) 2006-01-31
CN1305491A (zh) 2001-07-25
US6946459B2 (en) 2005-09-20
EP1070083A1 (fr) 2001-01-24
EE200000586A (et) 2002-02-15
TR200002914T2 (tr) 2001-02-21
IL138818A (en) 2008-11-26
BG104829A (en) 2001-05-31
YU60800A (sh) 2002-11-15
DE69929315D1 (de) 2006-03-30
FR2777279B1 (fr) 2004-08-13
NO20005060D0 (no) 2000-10-06
GEP20032974B (en) 2003-05-27
PL197016B1 (pl) 2008-02-29
AP2000001939A0 (en) 2000-12-31
AP1734A (en) 2007-03-22
SK14882000A3 (sk) 2001-04-09
DE69929315T2 (de) 2006-08-17
AR018328A1 (es) 2001-11-14
AU758042B2 (en) 2003-03-13
KR20010034759A (ko) 2001-04-25
WO1999052935A1 (fr) 1999-10-21
TW522152B (en) 2003-03-01
ZA200005438B (en) 2002-01-07
SI1070083T1 (sl) 2006-04-30
CZ20003678A3 (cs) 2001-02-14
DK1070083T3 (da) 2006-05-15
UA71563C2 (uk) 2004-12-15
HUP0101586A2 (hu) 2001-11-28
ATE315044T1 (de) 2006-02-15
HRP20000665A2 (en) 2001-08-31
NO20005060L (no) 2000-10-06
US20030171365A1 (en) 2003-09-11
NO327995B1 (no) 2009-11-02
HUP0101586A3 (en) 2002-11-28
ID26290A (id) 2000-12-14
US6544977B1 (en) 2003-04-08
NZ507199A (en) 2002-12-20
KR100582981B1 (ko) 2006-05-24
ME01627B (me) 2008-09-29
HU227561B1 (en) 2011-08-29
IL168047A (en) 2011-10-31
PL343350A1 (en) 2001-08-13
RS49916B (sr) 2008-09-29
SK286267B6 (sk) 2008-06-06
CU23055A3 (es) 2005-06-24

Similar Documents

Publication Publication Date Title
BR0209845A (pt) Formas de dosagem de oxcarbazepina e processo para a preparação das mesmas
BRPI9912156B8 (pt) processo para a preparação do sal de (3s)-tetraidro-3-furanil-(1s,2r)-3-[[(4-aminofenil)-sulfonil] (isobutil)amino]-1-benzil-2-fosfonóxi)propilcarbamato de cálcio em uma forma cristalina
EA200200183A1 (ru) Композиция, содержащая трамадол и противосудорожное лекарственное средство
BR0014441A (pt) Composições que apresentam estabilidade aperfeiçoada
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BR0016227A (pt) Derivados de adamantano
BR9713363A (pt) Epotilonas c, d, e e f, preparação e composições
BR9911160A (pt) Ciclosporinas
ATE146360T1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
DE59703796D1 (de) Karamellen enthaltend ein süssungsmittel
BR9912240A (pt) Benzocicloheptenos, processo para a sua preparação, preparados farmacêuticos, que contêm os mesmos bem como seu emprego para a preparação de medicamentos
ATE273693T1 (de) Proteinhaltige arzneimittel
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
BR9812773A (pt) &#34;alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados&#34;
BR9909549A (pt) Formas cristalinas do 1s-[1alfa(2s*,3r*),9alfa]-6, 10-dioxo-n(2-etóxi-5-oxo-tetrahidro-3-furanil)-9-[[(1-is oquinolil)carbonil]-amino]octa-hidro-6h-piridazino[1 ,2-a][1,2]diazepina-1-carboxamida
BR0113650A (pt) N-(3,5-dicloro-2-metoxifenil)-4-metóxi-3-piperazina-1-il a-benzenossulfonamida
BR0111055A (pt) Formulação farmacêutica, e, processo para a preparação e uso da mesma
BR9808126A (pt) Quinoxalinodionas
GEP20043377B (en) Pharmaceutical Complex
HUP0102075A2 (hu) Stabil mitoxantron-oldatok, eljárás az előállításukra
BR9809457A (pt) Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia.
AU3739500A (en) Protease resistant flint analogs
CO5070673A1 (es) Composiciones farmaceuticas en forma de solucion estable que comprenden (1s,4r)-cis-4-(2-amino-6-(ciclopropilamino)-9h -purin-9-il)-2-ciclopenteno-1-metanol, un quelador de metal y un agente endulzante

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AVENTIS PHARMA S.A. (FR)

Free format text: TRANSFERIDO POR FUSAO DE: HOECHST MARION ROUSSEL

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07K 5/023, A61K 38/06

Ipc: C07K 5/023 (2006.01), A61K 38/06 (2006.01), A61P 2

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.